Skip to main content
Clinical Trials/NCT03889340
NCT03889340
Completed
Not Applicable

Study of Brain Cools Device in Patients Resuscitated From Cardiac Arrest

Adam Frisch1 site in 1 country38 target enrollmentMay 1, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Cardiac Arrest With Successful Resuscitation
Sponsor
Adam Frisch
Enrollment
38
Locations
1
Primary Endpoint
Rate of hypothermia induction
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

This submission is a pilot in which the new IQool Warming System device will be used to maintain the temperature of adult patients in cardiac arrest within a range of within a range of 32°C to 38.5°C (89.6°F to 101.3°F). The IQool Warming System has received a 510 K Clearance by the FDA.

Detailed Description

Subjects will receive temperature management using the IQool. This is an FDA approved device. Managing temperature is part of standard care for this population and surface cooling is commonly employed. The following phases will be conducted as standard of care, and will be reviewed for this study: Induction phase: When a subject is included in the study, the IQool will be connected to the patient and activated. The induction period will continue until the patient has reached the upper limit of the target temperature range (defined as 0.5°C above the target temperature). Maintenance phase: Set target temperature will be maintained for 24 hours. The maintenance phase begins when the subject temperature is within 0.5°C of goal temperature. The maintenance phase is completed 24 hours after first reaching below the upper limit of the target temperature range. Rewarming phase: After 24 hours of maintenance, gradual rewarming at 0.25 °C/h will commence. When the subject reaches 37°C the TTM period is completed and the IQool will continue to provide fever control. Post TTM fever control: The subject will be kept at a body temperature of 37°C until 72 hours after the cardiac arrest or earlier if the subject regains consciousness.

Registry
clinicaltrials.gov
Start Date
May 1, 2019
End Date
December 1, 2021
Last Updated
4 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Adam Frisch
Responsible Party
Sponsor Investigator
Principal Investigator

Adam Frisch

Assistant Professor of Emergency Medicine

University of Pittsburgh

Eligibility Criteria

Inclusion Criteria

  • In- or out-of-hospital cardiac arrest of all initial rhythms
  • Adult patients (18 years of age and older)
  • Unconscious on admission to hospital, defined as not following commands
  • Indication for targeted temperature management

Exclusion Criteria

  • Pregnancy
  • Active do not resuscitate order
  • Any patient not expected to survive 72 hours
  • Skin infection
  • Skin wound affecting site of temperature exchange pads

Outcomes

Primary Outcomes

Rate of hypothermia induction

Time Frame: Up to 12 hours

Induction of hypothermia will occur at a rate of at least 1C/hr

Maintenance of hypothermia

Time Frame: 24 hours

The IQool system will maintain temperature within 0.5C of goal temperature for 75% of the maintenance phase

Rewarming rate

Time Frame: Up to16 hours

When rewarming, the IQool system will rewarm within 0.5C of the goal rate of rewarming

Secondary Outcomes

  • Number of physicians that recommend the IQool system for temperature management(72 hours)

Study Sites (1)

Loading locations...

Similar Trials